Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.
You may also be interested in...
Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
"The idea of giving up and going home is simply not in the cards," CEO Mills says.
Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
"The idea of giving up and going home is simply not in the cards," CEO Mills says.
Osiris/Genzyme Anticipate Approval Of Stem Cell Therapy Prochymal By 2010
Submission for graft-versus-host disease indication begins under a rolling BLA this quarter, with final data due at mid-year and a possible six-month review for the first therapy of its kind.